Telomere/telomerase system: A new target of statins pleiotropic effect?

Current Vascular Pharmacology

Volumn 10, Issue 2, 2012, Pages 216-224

  Olivieri, Fabiola ^a,b   Mazzanti, Ilaria ^b   Abbatecola, Angela M ^b   Recchioni, Rina ^b   Marcheselli, Fiorella ^b   Procopio, Antonio D ^a,b   Antonicelli, Roberto ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

Statins; Telomerase; Telomeres

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TELOMERASE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; BACTEREMIA; BIOAVAILABILITY; CELL AGING; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; LEUKOCYTE; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PLEIOTROPY; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; TELOMERE; TELOMERE HOMEOSTASIS;

AGED; AGED, 80 AND OVER; ANIMALS; CELL AGING; DNA DAMAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES; TELOMERASE; TELOMERE; TELOMERE SHORTENING;

EID: 84857134035     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112799305076     Document Type: Review

References (131)

1. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-4.
2. Biasucci LM, Biasillo G, Stefanelli A. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clin Chem Lab Med 2010; 48: 1685-91.
3. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002; 42: 835-45.
4. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99: 95-112.
5. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010; 74: 818-26.
6. Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol 2008; 101:1009-15.
7. Sinensky M. Recent advances in the study of prenylated proteins. Biochim Biophys Acta 2000; 1484: 93-106.
8. Ali BR, Nouvel I, Leung KF, Hume AN, Seabra MC. A novel statin-mediated "prenylation block-and-release" assay provides insight into the membrane targeting mechanisms of small GTPases. Biochem Biophys Res Commun 2010; 397: 34-41.
9. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 2005; 20: 133-6.
10. Wagner RJ, Martin KA, Powell RJ, Rzucidlo EM. Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR. Am J Physiol Cell Physiol 2010; 299: C119-27.
11. Balakumar P, Mahadevan N. Interplay between statins and PPARs in improving cardiovascular outcomes: A double-edged sword? Br J Pharmacol 2011.
12. Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 2010; 86: 211-8.
13. Li J, Li JJ, He JG, Nan JL, Guo YL, Xiong CM. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factorkappaB pathway. Cardiovasc Ther 2010; 28: 8-14.
14. Bu DX, Griffin G, Lichtman AH. Mechanisms for the antiinflammatory effects of statins. Curr Opin Lipidol 2011; 22: 165-70.
15. Hong H, Zeng JS, Kreulen DL, Kaufman DI, Chen AF. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am J Physiol Heart Circ Physiol 2006; 291: H2210-5.
16. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108: 1567-74.
17. Manfredini V, Biancini GB, Vanzin CS, et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients. Cell Biochem Funct 2010; 28: 360-6.
18. Manfredini V, Biancini GB, Vanzin CS, et al. Apolipoprotein, Creactive protein and oxidative stress parameters in dyslipidemic type 2 diabetic patients treated or not with simvastatin. Arch Med Res 2010; 41: 104-9.
19. Ni W, Egashira K, Kataoka C, et al. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001; 89: 415-21.
20. Aoki C, Nakano A, Tanaka S, et al. Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells. Int J Cardiol 2010.
21. Casani L, Sanchez-Gomez S, Vilahur G, Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 2005; 94: 1035-41.
22. Shen W, Shi HM, Fan WH, Luo XP, Jin B, Li Y. The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbit. Mol Biol Rep 2011; 38: 3821-8.
23. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
24. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001; 131: 41-6.
25. Sadeghi MM, Tiglio A, Sadigh K, et al. Inhibition of interferongamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001; 71: 1262-8.
26. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-56.
27. Tziakas DN, Chalikias GK, Stakos D, et al. Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic effect? Cardiovasc Drugs Ther 2009; 23: 471-80.
28. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92: 1049-55.
29. Brouilette SW, Moore JS, McMahon AD, et al.; West of ScotlandCoronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369: 107-14.
30. Satoh M, Minami Y, Takahashi Y, Tabuchi T, Itoh T, Nakamura M. Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease. Clin Sci (Lond) 2009; 116: 827-35.
31. Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 2011; 9: 62-86.
32. Keating GM. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs 2011; 11: 227-47.
33. Pate M, Damarla V, Chi DS, Negi S, Krishnaswamy G. Endothelial cell biology: role in the inflammatory response. Adv Clin Chem 2010; 52: 109-30.
34. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58-63.
35. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-9.
36. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
37. Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of reninangiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci (Lond) 2010; 119: 395-405.
38. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function and recent clinical trials. Biochim Biophys Acta 2010; 1803: 1231-43.
39. Li L, Chen X-P, Li Y-J. MicroRNA-146a and Human Disease. Scand J Immunol 2010; 71: 227-31.
40. Brandes RP, Schröder K. Differential vascular functions of Nox family NADPH oxidases. Curr Opin Lipidol 2008; 19: 513-8.
41. Otto A, Fontaine J, Tschirhart E, Fontaine D, Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway. Br J Pharmacol 2006; 148: 544-52.
42. Guasti L, Marino F, Cosentino M, et al. Prolonged statin associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur Heart J 2008; 29: 1118-26.
43. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes 2010; 59: 1528-38.
44. Groemping Y, Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J 2005; 386: 401-16.
45. Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekström L. Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 2011.
46. Liu S, He Y, Dou Y, et al. Caveolin-1 restoration by cholesterol enhances the inhibitory effect of simvastatin on arginine vasopressin-induced cardiac fibroblasts proliferation. Mol Cell Biochem 2009; 331: 173-80.
47. Kukliska AM, Mroczko B, Musia WJ, et al. Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress. Pharmacol Rep 2010; 62: 883-90.
48. Shammas MA. Telomeres, lifestyle, cancer, and aging. Curr Opin Clin Nutr Metab Care 2011; 14: 28-34
49. Xu Y. Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA. Chem Soc Rev 2011; 40: 2719-40.
50. Wong JM, Collins K. Telomere maintenance and disease. Lancet 2003; 362: 983-8.
51. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010; 464: 520-8.
52. Harrington L. Biochemical aspects of telomerase function. Cancer Lett 2003; 194:139-54.
53. Martínez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 2011; 11: 161-76.
54. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
55. Ota H, Eto M, Kano MR, et al. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol 2010; 30: 2205-11.
56. Yokoi T, Fukuo K, Yasuda O, et al. Apoptosis signal-regulating kinase 1 mediates cellular senescence induced by high glucose in endothelial cells. Diabetes 2006; 55: 1660-5.
57. Matthews C, Gorenne I, Scott S, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res 2006; 99: 156-64.
58. Nakano-Kurimoto R, Ikeda K, Uraoka M, et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol 2009; 297: H1673-84.
59. Burton DG, Matsubara H, Ikeda K. Pathophysiology of vascular calcification: Pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol 2010; 45: 819-24.
60. Son BK, Kozaki K, Iijima K, et al. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphateinduced calcification of vascular smooth muscle cells. Eur J Pharmacol 2007; 556: 1-8.
61. Ragnauth CD, Warren DT, Liu Y, et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121: 2200-10.
62. Yudoh K, Karasawa R. Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA). Aging (Albany NY) 2010; 2: 990-8.
63. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5.
64. Nubel T, Damrot J, Roos WP, Kaina B, Fritz G. Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res 2006; 12: 933-9.
65. Mahmoudi M, Gorenne I, Mercer J, Figg N, Littlewood T, Bennett M. Statins use a novel nijmegen breakage syndrome-1-dependent pathway to accelerate dna repair in vascular smooth muscle cells. Circulation Res 2008; 103: 717-25.
66. Wang Z, Rhee DB, Lu J, et al. Characterization of oxidative guanine damage and repair in mammalian telomeres. PLoS Genet 2010; 6: e1000951.
67. Puccetti L, Santilli F, Pasqui AL, et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 2011; 214: 122-8.
68. Chen JW, Zhou SB, Tan ZM. Aspirin and pravastatin reduce lectinlike oxidized low density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells. Chin Med J (Engl) 2010; 123: 1553-6.
69. Haendeler J, Hoffmann J, Diehl JF, et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 2004; 94: 768-75.
70. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004; 110: 3136-42.
71. Zhu XD, Kuster B, Mann M, Petrini JH, de Lange T. Cell-cycleregulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet 2000; 25: 347-52.
72. Chai W, Sfeir AJ, Hoshiyama H, Shay JW, Wright WE. The involvement of the Mre11/Rad50/Nbs1 complex in the generation of G-overhangs at human telomeres. EMBO Rep 2006; 7: 225-30.
73. Subramanian L, Moser BA, Nakamura TM. Recombination-based telomere maintenance is dependent on Tel1-MRN and Rap1 and inhibited by telomerase, Taz1, and Ku in fission yeast. Mol Cell Biol 2008; 28: 1443-55.
74. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res 2007; 100: 15-26.
75. De Caterina, R. Endothelial dysfunctions: Common denominators in vascular disease. Curr Opin Clin Nutr Metab Care 2000; 3: 453-67.
76. Bonetti PO, Lerman LO, Lerman, A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.
77. Dilaveris P, Giannopoulos G, Riga M, Synetos A, Stefanadis C. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007; 5: 227-37.
78. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection--more than just lipid lowering? Pharmacol Ther 2009; 122: 30-43.
79. Harris MB, Blackstone MA, Sood SG, et al. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004; 287: H560-6.
80. Ghaffari N, Ball C, Kennedy JA, Stafford I, Beltrame JF. Acute modulation of vasoconstrictor responses by pravastatin in small vessels. Circ J 2011; 75: 1506-14.
81. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87: 616-22.
82. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: Role of microdomains and oxidative stress. Circulation 2004; 109: II34-41.
83. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulation 2003; 108: 2292-7.
84. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med 2008; 359: 2195-207.
85. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.
86. Fadini GP, Maruyama S, Ozaki T, et al. Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One 2010; 5: e11488.
87. Fadini GP, de Kreutzenberg S, Agostini C, et al. Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis 2009; 207: 213-9.
88. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
89. Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Arterioscler Thromb Vasc Biol 2002; 22: 1567-72.
90. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-90.
91. Fadini GP, Albiero M, Boscaro E, et al. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol Int 2010; 34: 709-15.
92. Rupp S, Badorff C, Koyanagi M, et al. Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. Basic Res Cardiol 2004; 99: 61-8.
93. Zhao TT, Trinh D, Addison CL, Dimitroulakos J. Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors. PLoS One 2010; 5: e12563.
94. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
95. Kusuyama T, Omura T, Nishiya D, et al. The effects of HMG-CoA reductase inhibitor on vascular progenitor cells. J Pharmacol Sci 2006; 101: 344-9.
96. Thum T, Fraccarollo D, Galuppo P, et al. Bone marrow molecular alterations after myocardial infarction: impact on endothelial progenitor cells. Cardiovasc Res 2006; 70: 50-60.
97. Leone AM, Rutella S, Giannico MB, et al. Effect of intensive vs. standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: STatins for Regeneration after Acute myocardial infarction and PCI (STRAP) trial. Int J Cardiol 2008; 130: 157-62.
98. Tousoulis D, Kaski JC, Antoniades C, Stefanadis C. Beneficial effects of statin treatment after myocardial infarction: Is progenitor cell mobilization the missing link? Int J Cardiol 2008; 130: 301-3.
99. Hibbert B, Ma X, Pourdjabbar A, et al. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS One 2011; 6: e16413.
100. Minami Y, Satoh M, Maesawa C, et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest 2009; 39: 359-67.
101. Schmidt-Lucke C, Fichtlscherer S, Rössig L, Kämper U, Dimmeler S. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis 2010; 211: 249-54.
102. Fitzpatrick AL, Kronmal RA, Gardner JP, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol 2007; 165: 14-21.
103. Salpea KD, Humphries SE. Telomere length in atherosclerosis and diabetes. Atherosclerosis 2010; 209: 35-8.
104. Olivieri F, Lorenzi M, Antonicelli R, et al. Leukocyte telomere shortening in elderly type2DM patients with previous myocardial infarction. Atherosclerosis 2009; 206: 588-93.
105. Zee RY, Castonguay AJ, Barton NS, Germer S, Martin M. Mean leukocyte telomere length shortening and type 2 diabetes mellitus: a case-control study. Transl Res 2010; 155: 166-9.
106. Fyhrquist F, Tiitu A, Saijonmaa O, Forsblom C, Groop PH; FinnDiane Study Group. Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes. J Intern Med 2010; 267: 278-86.
107. Testa R, Olivieri F, Sirolla C, et al. Leukocyte telomere length is associated with type 2 diabetes mellitus complications. Diabetic Med 2011.
108. Tentolouris N, Nzietchueng R, Cattan V, et al. White blood cells telomere length is shorter in males with type 2 diabetes and microalbuminuria. Diabetes Care 2007; 30: 2909-15.
109. Tiwari A. Statins and telomere length: risk assessment and management for coronary heart disease. Expert Opin Ther Targets 2007; 11: 979-82.
110. Alexander KP, Newby LK, Cannon CP, et al.; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: Non-STsegment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115: 2549-69.
111. Burns M, Duff K. Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease. Neurochem Res 2003; 28: 979-86.
112. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 2011; 12: 284-96.
113. Abbatecola AM, Olivieri F, Corsonello A, Antonicelli R, Corica F, Lattanzio F. Genome-wide association studies: is there a genotype for cognitive decline in older persons with type 2 diabetes? Curr Pharm Des 2011; 17: 347-56.
114. Lukens JN, Van Deerlin V, Clark CM, Xie SX, Johnson FB. Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease. Alzheimers Dement 2009; 5: 463-9.
115. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-61.
116. Petanceska SS, DeRosa S, Olm V, et al. Statin therapy for Alzheimer's disease: Will it work? J Mol Neurosci 2002; 19: 155-61.
117. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev 2010; 8: CD007514.
118. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as anti-inflammatory agents? Circulation 2004; 109: II18-26.
119. Blanco-Colio LM, Munoz-Garcia B, Martin-Ventura JL, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 2003; 108: 1506-13.
120. McInnes IB, McCarey DW, Sattar N. Do statins offer therapeutic potential in inflammatory arthritis. Ann Rheum Dis 2004; 63: 1535-7.
121. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-8.
122. Potena L, Grigioni F, Ortolani P, et al. Safety and efficacy of early aggressive vs. cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. J Heart Lung Transplant 2011; 30: 1305-11.
123. Olyaei A, Greer E, Delos Santos R, Rueda J.The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients. Clin J Am Soc Nephrol 2011; 6: 664-78.
124. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-31.
125. Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 2004; 38: 205-8.
126. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001; 98: 13925-30.
127. Manes S, Del Real G, Lacalle RA, et al. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep 2000; 1: 190-6.
128. Del Real G, Jimenez-Baranda S, Mira E, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200: 541-7.
129. Kouroumichakis I, Papanas N, Proikaki S, Zarogoulidis P, Maltezos E. Statins in prevention and treatment of severe sepsis and septic shock. Eur J Intern Med 2011; 22: 125-33.
130. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: A population-based cohort analysis. Lancet 2006; 367: 413-8.
131. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest 2003; 124: 740-3.